SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...
Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the ...
Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results